Drugs / PVT-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04840004 | Mar 2021 → Dec 2025 | cancer of unknown primary site, non-small cell lung carcinoma, refractory malignant neoplasm | PlusVitech S.L. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PVT-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04840004 ↗ |
| Route | Oral | “PVT-1 is a safe, orally administrable and well-tolerated drug” NCT04840004 ↗ |